Research outlook

Where Waldenström macroglobulinemia treatment is heading

Waldenström macroglobulinemia · Updated Nov 14, 2026

Waldenström macroglobulinemia (WM) is a slow-growing blood cancer in which abnormal B cells fill the bone marrow and make large amounts of an antibody called IgM, which can thicken the blood and damage nerves. About 1,000 to 1,500 Americans are diagnosed each year, mostly over 65. Most cases carry a MYD88 mutation, which makes WM very sensitive to BTK inhibitor pills. Those pills are taken indefinitely, so trials now test time-limited combinations, BCL2 inhibitors, BTK degraders and radioactive drugs.

  1. Now

    Nov 2026

    Better-tolerated BTK inhibitorsHappened 36.3% deep responses

    Zanubrutinib gave deep responses in 36.3% vs 25.3% with ibrutinib, with less atrial fibrillation.

    36.3%: very good partial or complete response with zanubrutinib, vs 25.3% with ibrutinib.

    Long-lasting controlHappened 94.6% response rate

    Acalabrutinib responses held for more than 5 years in many patients.

    94.6%: response rate in relapsed disease.

    An option after BTK inhibitorsHappened 82.5% response rate

    Pirtobrutinib worked in 81.0% of people who had already taken a covalent BTK inhibitor.

    82.5%: response rate.

  2. 6 months

    by May 2027

    BCL2 inhibitor combinationsPossible

    BeOne's sonrotoclax plus zanubrutinib trial (114 people) finishes September 2026.

  3. 12 months

    by Nov 2027

    A BTK degraderPossible

    Tacabrutideg, which destroys the BTK protein instead of blocking it, is in a large study (689 people) due March 2027.

    Testing for CXCR4Possible 72% 4-year progression-free

    CXCR4 mutation status increasingly guides whether to add rituximab.

    72%: 4-year progression-free with rituximab in CXCR4-mutated WM, vs 43%.

  4. 3 years

    by late 2029

    Time-limited treatmentPossible

    ECWM-2 and an NCI trial test venetoclax with rituximab (both due March 2028); a French trial tests fixed-duration zanubrutinib plus sonrotoclax (due December 2028).

  5. 5 years

    by late 2031

    Pills vs chemotherapy, head to headPossible

    RAINBOW (148 people) compares ibrutinib-rituximab with chemoimmunotherapy; due March 2030.

    A radioactive drugLong shot

    Cellectar's iopofosine I-131 phase 3 (219 people) is due January 2032.

Happened Likely Possible Long shot

The research paths

Rising

BTK inhibitors and degraders

82.5% response rate
Details and 2 trialsHide
Rising

Time-limited combinations

72% 4-year progression-free
Details and 5 trialsHide
Active

Head-to-head and radioactive drugs

Details and 2 trialsHide

Borrowed from other cancers

From Chronic lymphocytic leukemia

Venetoclax and sonrotoclax

Phase 2

BCL2 inhibitors that allow fixed-length treatment in CLL.

From CLL and mantle cell lymphoma

Pirtobrutinib

Phase 1/2

A non-covalent BTK inhibitor approved for CLL and mantle cell lymphoma.

From Multiple myeloma

Carfilzomib

Phase 2

A proteasome inhibitor added to ibrutinib.

Open to join now

See every recruiting WM trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today
Sonrotoclax with zanubrutinibTime-limited combinations
Sep 2026
Tacabrutideg (BGB-16673), a BTK degraderBTK inhibitors and degraders
Mar 2027
Venetoclax-rituximab vs DRC (ECWM-2)Time-limited combinations
Mar 2028
Mar 2028
May 2028
Dec 2028
Jan 2029
Mar 2030
Iopofosine I-131 vs R-CDHead-to-head and radioactive drugs
Jan 2032

What just happened

Acalabrutinib responses last beyond 5 years

ACE-WM-001, Blood Advances.

Pirtobrutinib works after other BTK inhibitors

BRUIN, Lancet Haematology.

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See WM trials recruiting now →

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.